Latest Healthcare News

Zoetis lifted its full-year adjusted earnings outlook after a mixed third quarter, but US companion animal revenue fell 8% amid price sensitivity, competition and generic pressure. The animal health group also reported an 18% drop in GAAP net income and a US$89 million impairment charge.

Cardinal Health has lifted its fiscal 2027 earnings outlook after a strong opening quarter, with revenue reaching US$67.5 billion and non-GAAP diluted EPS rising 28%. The healthcare distributor also completed a US$500 million share repurchase and advanced several strategic initiatives.

BD finished fiscal 2026 with higher revenue, adjusted earnings and cash generation, while setting low single-digit growth expectations for the year ahead. Its proposed US$19 billion US investment adds scale to the strategy, but remains tied to milestones and future implementation.

The Cigna Group raised its 2026 adjusted earnings outlook after third-quarter revenue rose 6%, while pharmacy benefit pressure kept underlying profit broadly flat. The health insurer also unveiled a US$3 billion modernisation and productivity programme targeting longer-term growth.

STERIS delivered 9% second-quarter revenue growth and lifted its fiscal 2027 adjusted EPS outlook, helped partly by tariff refunds. Life Sciences led the operating gains, while weaker cash flow and a new restructuring plan add important qualifications.

Edwards Lifesciences delivered stronger-than-expected third-quarter growth and lifted its full-year 2026 outlook, led by a sharp rise in mitral and tricuspid therapies. A US$220.2 million impairment charge remains a notable counterpoint to the upbeat operating performance.

McKesson delivered a strong fiscal second quarter, with revenue up 8% and adjusted diluted EPS rising 18%. The healthcare distributor lifted its full-year adjusted EPS guidance while expanding its specialty-care portfolio through new investments and acquisitions.

Charles River Laboratories delivered a second consecutive quarter of organic revenue growth and raised its 2026 outlook, despite reported revenue falling after divestitures. The quarter’s sharp GAAP earnings increase was heavily amplified by a US$245.6 million tax reserve reversal.

Insulet delivered a stronger-than-expected third quarter, with revenue up 19.2% and adjusted earnings per share rising nearly 60%. The diabetes-device maker also raised its operating-margin outlook and authorised a US$1 billion share repurchase programme.

Cencora delivered a stronger fiscal 2026, with adjusted earnings per share rising 12.3% and quarterly profit benefiting from the OneOncology acquisition. The healthcare distributor expects another 8% to 10% increase in adjusted EPS in fiscal 2027, while reshaping its reporting structure and lifting its dividend.

CVS Health plans to separate its healthcare solutions and retail pharmacy businesses by the first half of 2028, while raising its 2026 earnings and cash-flow targets. The announcement came alongside stronger third-quarter results, though management flagged elevated cost trends and potential macroeconomic pressure.

Zimmer Biomet lifted its full-year 2026 sales and adjusted earnings guidance after third-quarter constant-currency growth accelerated to 3.7%. The result was supported by strong hips, sports medicine and technology sales, although GAAP earnings fell and knees remained a weak spot.